Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability

Author(s): Ferruccio de Lorenzo, Michael Feher, Juliette Martin, Sophie Collot-Teixeira, Olena Dotsenko and John Louis McGregor

Volume 13 , Issue 28 , 2006

Page: [3385 - 3393] Pages: 9

DOI: 10.2174/092986706779010324

Price: $65

Abstract

Primarily statin drugs inhibit hepatic 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA)reductase, which is responsible for the reduction in circulating low-density lipoprotein (LDL) cholesterol.Several findings from recent research studies indicate that statins have multiple actions that favorablyinfluence key factors involved in the atherogenic process. These so-called pleiotropic properties affect variousaspects of cell function, inflammation, coagulation, and vasomotor activity. These effects are mediated eitherindirectly through LDL cholesterol reduction or via a direct effect on cellular functions. Such actions maycontribute to the early cardiovascular benefit observed in several outcome trials with statin drugs therapy.Although many of the pleiotropic properties of statins may be a class effect, some may be unique to certainagents and account for differences in their pharmacological activity. This review summarise the results of the major outcome trials of statins and non-statins therapy and thepossible mechanisms beyond lipid lowering contributing to plaque stability.

Keywords: Statins, pleiotropic effects, plaque stability, lipid lowering agents, coronary heart disease, thrombosis


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy